Ruthenium/Other Metals
2023
-
C. Weng, Y. L. K. Tan, W. G. Koh, W. H. Ang*,
Harnessing Transition Metal Scaffolds for Targeted Antibacterial Therapy,
Angew. Chem. Int. Ed.,
2023,
62,
e202310040
-
C. Weng, H. Yang, B. S. Loh, M. W. Wong*, W. H. Ang*,
Targeting Pathogenic Formate-Dependent Bacteria with a Bioinspired Metallo–Nitroreductase Complex,
J. Am. Chem. Soc.,
2023,
145,
6453-6461
-
J. Arakelyan, D. A. Rusanov, M. R. Chang, A. V. Asaturova, G. S. Kireeva, M. Alshehri, W. H. Ang, M. V. Babak,
Targeting emerging cancer hallmarks by transition metal complexes: Epigenetic reprogramming and epitherapies. Part II,
Coord. Chem. Rev.,
2023,
475,
214899
-
M. R. Chang, D. A. Rusanov, J. Arakelyan, M. Alshehri, A. V. Asaturova, G. S. Kireeva, M. V. Babak, W. H. Ang,
Targeting emerging cancer hallmarks by transition metal complexes: Cancer stem cells and tumor microbiome. Part I,
Coord. Chem. Rev.,
2023,
475,
214923
2022
-
I. Kuznetcova, F. Bacher, S. M., Alfadul, M. J. R. Tham MJR, W. H. Ang, M. V. Babak, P. Rapta, V. B. Arion VB,
Elucidation of Structure-Activity Relationships in Indolobenzazepine-Derived Ligands and Their Copper(II) Complexes: The Role of Key Structural Components and Insight into the Mechanism of Action,
Inorg. Chem.,
2022,
61,
10167-10181
2021
-
C. Weng,* L. Shen, J. W. Teo, Z. C. Lim, B. S. Loh, and W. H. Ang*,
Targeted Antibacterial Strategy Based on Reactive Oxygen Species Generated from Dioxygen Reduction Using an Organoruthenium Complex,
JACS Au,
2021,
1,
1348-1354
-
M. V. Babak,* K. R. Chong, P. Rapta, M. Zannikou, H. M. Tang, L. Reichert. M. R. Chang, V. Kushnarev, P. Heffeter, S. M. Meier-Menches, Z. C. Lim, J. Y. Yap, A. Casini, I. V. Balyasnikova, W. H. Ang* ,
Interfering with Metabolic Profile of Triple-Negative Breast Cancer using Rationally-Designed Metformin Prodrugs,
Angew. Chem. Int. Ed.,
2021,
60,
13405-13413
2020
-
K. Ohui, I. Stepanenko, I. Besleaga, M. V. Babak, R. Stafi, D. Darvasiova, G. Giester, V. Pósa, E. A. Enyedy, D. Vegh, P. Rapta, W. H. Ang, A. Popović-Bijelić, V. B. Arion.*,
Triapine Derivatives Act as Copper Delivery Vehicles to Induce Deadly Metal Overload in Cancer Cells,
Biomolecules,
2020,
10,
1336
-
C. Weng, L. Shen, W. H. Ang*,
Harnessing Endogenous Formate for Antibacterial Prodrug Activation by in cellulo Ruthenium-Mediated Transfer Hydrogenation Reaction,
Angew. Chem. Int. Ed.,
2020,
59,
9314-9318
-
H. V. Le, M. Babak, M. A. Ehsan, M. Altaf, L. Reichert, A. L. Gushchin, W. H. Ang,* A. A. Isab*,
Highly cytotoxic gold(I)-phosphane dithiocarbamate complexes trigger an ER stress-dependent immune response in ovarian cancer cells,
Dalton Trans,
2020,
49,
7355-7363
2018
-
E. Orlowska, M. V. Babak, O. Dömötör, E. A. Enyedy, P. Rapta, M. Zalibera, L. Bučinský, M. Malček, C. Govind, V. Karunakaran, Y. C. S. Farid, T. E. McDonnell, D. Luneau, D. Schaniel, W. H. Ang, and V. A. Arion*,
NO Releasing and Anticancer Properties of Octahedral Ruthenium− Nitrosyl Complexes with Equatorial 1H‑Indazole Ligands,
Inorg. Chem.,
2018,
57,
10702-10717
-
M. V. Babak* and W. H. Ang*,
Multinuclear Organometallic Ruthenium-Arene Complexes for Cancer Therapy (Book Chapter),
Metal Ions in Life Sciences,
2018,
18,
171-194
-
M. J. Chow,* M. V. Babak, K. W. Tan, M. C. Cheong, G. Pastorin, C. Gaiddon and W. H. Ang*,
Induction of the Endoplasmic Reticulum Stress Pathway by Highly Cytotoxic Organoruthenium Schiff-Base Complexes,
Mol. Pharmaceutics,
2018,
15,
3020-3031
2017
-
M.J. Chow* and W.H. Ang*,
Organoruthenium(II)-Arene Complexes: Structural Building Blocks for Anticancer Drug Discovery (Book Chapter),
Inorganic and Organometallic Transition Metal Complexes with Biological Molecules and Living Cells,
2017,
117-146
-
M. J. Chow, M. Alfiean, G. Pastorin, C. Gaiddon and W. H. Ang*,
Apoptosis-independent organoruthenium anticancer complexes that overcome multidrug resistance: self-assembly and phenotypic screening strategies ,
Chem. Sci.,
2017,
8,
3641-3649
-
A. Sîrbu, O. Palamarciuc, M. V. Babak,* J. M. Lim, K. Ohui, E. A. Enyedy, S. Shova, D. Darvasiová, P. Rapta, W. H. Ang,* and V. B. Arion* ,
Copper(II) thiosemicarbazone complexes induce marked ROS accumulation and promote nrf2-mediated antioxidant response in highly resistant breast cancer cells,
Dalton Trans.,
2017,
46,
3833-3847
2016
-
M. J. Chow, M. V. Babak, D. Y. Q. Wong, G. Pastorin, C. Gaiddon,* W. H. Ang*,
Structural Determinants of p53-Independence in Anticancer Ruthenium-Arene Schiff-base Complexes,
Mol. Pharmaceutics,
2016,
13,
2543–2554
-
M. J. Chow, C. Licona, G. Pastorin, G. Mellitzer, W. H. Ang,* and C. Gaiddon*,
Structural tuning of organoruthenium compounds allows oxidative switch to control ER stress pathways and bypass multidrug resistance,
Chem. Sci.,
2016,
7,
4117-4124
2014
-
Z. Adhireksan, G. E. Davey, P. Campomanes, M. Groessl, C. M. Clavel, H. Yu, A. A. Nazarov, C. H. F. Yeo, W. H. Ang, P. Dröge, U. Rothlisberger, P. J. Dyson and C. A. Davey*,
Ligand substitutions between ruthenium–cymene compounds can control protein versus DNA targeting and anticancer activity,
Nat. Commun.,
2014,
5,
3462
-
M. J. Chow, C. Licona, D. Y. Q. Wong, G. Pastorin, C. Gaiddon, W. H. Ang*,
Discovery and Investigation of Anticancer Ruthenium Arene Schiff-Base Complexes via Water-Promoted Combinatorial Three-Component Assembly,
J. Med. Chem.,
2014,
57,
6043-6059
2013
-
P. Paira, M. J. Chow, G. Venkatesan, V. K. Kosaraju, S. L. Cheong, K.-N. Klotz, W. H. Ang*, G. Pastorin*,
Organoruthenium Antagonists of Human A3 Adenosine Receptors,
Chem. Eur. J.,
2013,
19,
8321-8330
2012
-
J. X. Ong, C. W. Yap, W. H. Ang*,
Rational Design of Selective Organoruthenium Inhibitors of Protein Tyrosine Phosphatase 1B,
Inorg. Chem.,
2012,
51,
12483-12492
-
A. Astarina, M. J. Chow, W. H. Ang*,
Transcription Inhibition by Organometallic Ruthenium–Arene Anticancer Complexes in Live Mammalian Cells,
Aust. J. Chem.,
2012,
65,
1271-1276
-
A. A. Nazarov, J. Risse, W. H. Ang, F. Schmitt, O. Zava, A. Ruggi, M. Groessl, R. Scopelitti, L. Juillerat-Jeanneret, C. G. Hartinger, P. J. Dyson,
Anthracene-Tethered Ruthenium(II) Arene Complexes as Tools To Visualize the Cellular Localization of Putative Organometallic Anticancer Compounds,
Inorg. Chem.,
2012,
51,
3633-3639
2011
-
Y. Q. Tan, P. J. Dyson, W. H. Ang*,
Acetal-Functionalized RAPTA Complexes for Conjugation and Labeling,
Organometallics,
2011,
30,
5965-5971
-
W. H. Ang, A. Casini, G. Sava, P. Dyson*,
Organometallic Ruthenium-Based Antitumor Compounds with Novel Modes of Action,
J. Organomet. Chem.,
2011,
696,
989-998
2009
-
W. H. Ang, L. J. Parker, A. De Luca, L. Juillerat-Jeanneret, C. J. Morton, M. Lo Bello, M. W. Parker, Paul J. Dyson*,
Rational Design of an Organometallic Glutathione Transferase Inhibitor,
Angew. Chem. Int. Ed. Engl.,
2009,
48,
3854-3857
-
W. H. Ang, Z. Grote, R. Scopelliti, L. Juillerat-Jeanneret, K. Severin, P. J. Dyson*,
Organometallic complexes that interconvert between trimeric and monomeric structures as a function of pH and their effect on human cancer and fibroblast cells,
J. Organomet. Chem.,
2009,
694,
968-972
2008
-
A. Mathieu, B. Therrien, G. Süss-Fink, P. Stepnicka, W. H. Ang, P. J. Dyson*,
Ferrocenoyl Pyridine Arene Ruthenium Complexes with Anticancer Properties: Synthesis, Structure, Electrochemistry, and Cytotoxicity,
Inorg. Chem.,
2008,
47,
578-583
-
F. Schmitt, P. Govindaswamy, G. Süss-Fink, W. H. Ang, P. J. Dyson, L. Juillerat-Jeanneret*, B. Therrien*,
Ruthenium-porphyrin compounds for photodynamic therapy of cancer,
J. Med. Chem.,
2008,
51,
1811-1816
2007
-
W. H. Ang*, A. De Luca, C. Chapuis-Bernasconi, L. Juillerat-Jeanneret, M. Lo Bello*,
Organometallic ruthenium inhibitors of glutathione-S-transferase P1-1 as anticancer drugs,
ChemMedChem,
2007,
2,
1799-1806
-
B. Therrien, W. H. Ang, F. Chérioux, L. Vieille-Petit, L. Juillerat-Jeanneret, G. Süss-Fink*, P. J. Dyson*,
Remarkable anticancer activity of triruthenium-arene clusters compared to tetraruthenium-arene clusters,
J. Cluster Sci.,
2007,
18,
741-752
-
A. Casini, G. Mastrobuoni, W. H. Ang, C. Gabbiani, G. Pieraccini, G. Moneti, P. J. Dyson*, L. Messori*,
ESI-MS characterization of protein adducts of anticancer ruthenium(II)-arene PTA (RAPTA) complexes,
ChemMedChem,
2007,
2,
631-635
-
W. H. Ang, E. Daldini, L. Juillerat-Jeanneret, P. J. Dyson*,
Strategy to tether organometallic ruthenium-arene anti-cancer compounds to recombinant human serum albumin,
Inorg. Chem.,
2007,
46,
9048-9050
-
W. H. Ang*,
Development of organometallic ruthenium(II) anticancer (RAPTA) drugs -Invited Paper-,
Chimia,
2007,
61,
140-142
-
C. A. Vock, W. H. Ang, C. Scolaro, L. Juillerat-Jeanneret*, G. Sava, P. J. Dyson*,
Synthesis, characterisation and in vitro evaluation of novel ruthenium(II) η6-arene complexes with MDR modulators as ligands,
J. Med. Chem.,
2007,
50,
2166 -2175
2006
-
W. H. Ang, P. J. Dyson*,
Classical and non-classical ruthenium-based anticancer drugs: towards targeted chemotherapy,
Eur. J. Inorg. Chem.,
2006,
20,
4003-4018
-
A. Dorcier, W. H. Ang, S. Bolaño, L. Gonsalvi, L. Juillerat-Jeannerat, G. Laurenczy, M. Peruzzini, A. D. Phillips, F. Zanobini, P. J. Dyson*,
In vitro evaluation of rhodium and osmium RAPTA analogues: the case for organometallic anticancer drugs not based on ruthenium,
Organometallics,
2006,
25,
4090-4096
-
W. H. Ang, E. Daldini, C. Scolaro, R. Scopelliti, L. Juillerat-Jeanneret, P. J. Dyson*,
Development of ruthenium arene anticancer drugs that resist hydrolysis,
Inorg. Chem.,
2006,
45,
9006-9013
